Dr. Kasper on Future Treatment Approaches in Sarcoma

Bernd Kasper, MD, PhD
Published: Wednesday, May 17, 2017



Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, discusses future treatment approaches in the field of sarcoma and the potential role of imatinib (Gleevac).

There are interesting data looking at Notch inhibition with a gamma secretase inhibitor in a small, phase II study of 17 patients, which demonstrated an overall response rate of 29%. Hopefully, this will lead to a larger study, Kasper adds, that could show that this could be an effective treatment option for patients.

Moreover, tyrosine kinase inhibitors, such as imatinib could also hold promise in patients with desmoid tumors, specifically in those who have progressive disease. However, this needs to be built into a strategy and used appropriately on an individualized basis, Kasper explains.
SELECTED
LANGUAGE


Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, discusses future treatment approaches in the field of sarcoma and the potential role of imatinib (Gleevac).

There are interesting data looking at Notch inhibition with a gamma secretase inhibitor in a small, phase II study of 17 patients, which demonstrated an overall response rate of 29%. Hopefully, this will lead to a larger study, Kasper adds, that could show that this could be an effective treatment option for patients.

Moreover, tyrosine kinase inhibitors, such as imatinib could also hold promise in patients with desmoid tumors, specifically in those who have progressive disease. However, this needs to be built into a strategy and used appropriately on an individualized basis, Kasper explains.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x